Measure of quality of life in patients with metastatic colorectal cancer: techniques and main results

被引:10
作者
Conroy, T
Guillemin, F
Kaminsky, MC
机构
[1] Ctr Alexis Vautrin, Dept Med Oncol, F-54511 Vandoeuvre Les Nancy, France
[2] Ecole Sante Publ, Fac Med, UPRES, EA Epidemiol Clin Prevent & Qual Vie, F-54500 Vandoeuvre Les Nancy, France
来源
REVUE DE MEDECINE INTERNE | 2002年 / 23卷 / 08期
关键词
colorectal cancer; quality of life; chemotherapy;
D O I
10.1016/S0248-8663(02)00645-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose. - Until the 1990s, the patient's duration of fife was the main measure for determining the value of palliative chemotherapy for colorectal cancer. Quality of life recently appeared as a main end point. The aim of this article is to provide an overview of the instruments used to measure quality of life in patients with metastatic colorectal cancer, to review the published data and to analyse the bias and methodological problems. Current knowledge and key points. - QoL is a multidimensional subjective concept, which can be measured using psychometric instruments. Quality of life measurement has a descriptive and prognostic value. Results from quality of life assessment in randomized trials have given useful information and help patients and physicians to choose between treatment options. More than half of the patients with palliative chemotherapy had at least stabilization of quality of life. Response to chemotherapy and side-effects influence quality of life. Quality of life assessment clearly requires methodological improvement. Missing data are a particularly difficult problem, which should be improved by a better organization. Future prospects and projects. - Psychometric properties of EORTC QLQ-CR38 et FACT-C should be checked in French language. An international consensus on methods of measurement of quality of life in oncology is warranted to enhance compliance, to better interpret quality of life results et to optimize publications of precise quality of life data. (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved.
引用
收藏
页码:703 / 716
页数:14
相关论文
共 84 条
[11]  
Borras JM, 2001, BMJ-BRIT MED J, V322, P1, DOI DOI 10.1136/BMJ.322.7290.826
[12]  
BOSSET JF, 1993, LYON CHIR, V89, P135
[13]   Nonspecific effects in longitudinal studies: Impact on quality of life measures [J].
Bouchet, C ;
Guillemin, F ;
Briancon, S .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (01) :15-20
[14]   A RANDOMIZED STUDY OF BOLUS FLUOROURACIL PLUS FOLINIC ACID VERSUS 21-DAY FLUOROURACIL INFUSION ALONE OR IN ASSOCIATION WITH CYCLOPHOSPHAMIDE AND MITOMYCIN-C IN ADVANCED COLORECTAL-CARCINOMA [J].
CAUDRY, M ;
BONNEL, C ;
FLOQUET, A ;
MARSAULT, C ;
QUETIN, P ;
PUJOL, J ;
MATON, O ;
DUJOLS, JP ;
CAUDRY, Y ;
SKAWINSKI, P ;
CARENCO, J ;
MOKHTARI, F ;
CELERIER, D ;
QUINTON, A ;
DEMEAUX, H ;
MAIRE, JP .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (02) :118-125
[15]   THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].
CELLA, DF ;
TULSKY, DS ;
GRAY, G ;
SARAFIAN, B ;
LINN, E ;
BONOMI, A ;
SILBERMAN, M ;
YELLEN, SB ;
WINICOUR, P ;
BRANNON, J ;
ECKBERG, K ;
LLOYD, S ;
PURL, S ;
BLENDOWSKI, C ;
GOODMAN, M ;
BARNICLE, M ;
STEWART, I ;
MCHALE, M ;
BONOMI, P ;
KAPLAN, E ;
TAYLOR, S ;
THOMAS, CR ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579
[16]   Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer [J].
Cocconi, G ;
Cunningham, D ;
Van Cutsem, E ;
Francois, E ;
Gustavsson, B ;
van Hazel, G ;
Kerr, D ;
Possinger, K ;
Hietschold, SM .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) :2943-2952
[17]  
Cohen SR, 1997, PALLIATIVE MED, V11, P3
[18]  
*COLL CANC COLL GR, 2000, BMJ-BRIT MED J, V321, P531
[19]  
Conroy T, 1999, J CLIN ONCOL, V17, P1644
[20]  
CONROY T, 2001, P AN M AM SOC CLIN, V20, pA401